Prosecution Lunch September 2010.

Slides:



Advertisements
Similar presentations
Prosecution Group Luncheon June, 2011 Patents. Clear and Convincing Survives Microsoft Corp. v. i4i Ltd. Pship (US 2011) §282 requires proof of invalidity.
Advertisements

Comments on the USPTO’s Proposed Streamlined Patent Reexamination Regulations Greg H. Gardella Elizabeth Iglesias Jason Sullivan Irell & Manella, LLP.
BLAW 2010 Patent Project Part 1I. Why do we have patent laws?
1 Examination Standard of Inventive Step in Taiwan Tony C. H. Lin Patent Attorney APAA Taiwan Group Lee and Li, Attorneys-at-Law November 18, 2007 in Adelaide.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
1 1 1 AIPLA American Intellectual Property Law Association USPTO Updates Including Glossary Pilot Program Chris Fildes Fildes & Outland, P.C. IP Practice.
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Determining Obviousness Under 35 U.S.C. § 103 After KSR v. Teleflex
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Prosecution Group Luncheon Patents July, Inequitable Conduct Post-Therasense American Calcar, Inc. v. American Honda Motor Co. (FC 2011) Inventors.
Patent Prosecution Luncheon March White House Patent Reform: Executive Actions Draft rule to ensure patent owners accurately record and regularly.
©2011 Haynes and Boone, LLP 1 Functional Language in Claims David O’Dell Haynes and Boone LLP
California :: Delaware :: Florida :: New Jersey :: New York :: Pennsylvania :: Virginia :: Washington, DC :: Advice for Drafting.
Obviousness II Class Notes: February 11, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Building and Maintaining BioPharma Patent Portfolios After KSR v. Teleflex: Strategies Addressing Higher Standards for Patentability Bruce D. Sunstein.
Patent Prosecution Luncheon February Defective Priority Claim Means No Priority Claim Each intermediate application in the chain of priority must.
Prosecution Lunch August All Ohio Annual Institute on IP Patent, Trademark and Copyright Updates Cincinnati – Tuesday, Sept. 21 8:30am - 4:45 pm.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 1 Enhancing Compact Prosecution RCEs and BPAI Appeals The Frequency and.
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex.
Claims, Anticipation, and Obviousness Kathleen Kahler Fonda Legal Advisor, Office of Patent Legal Administration July 30, 2010.
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex Biotech/Chem/Pharma Customer Partnership Meeting December.
1 Patent Claim Interpretation under Art. 69 EPC – Should prosecution history be used to interpret the patent? presented at Fordham 19th Annual Conference.
Claims and Determining Scope of Protection -Introduction Nov. 9, 2014 APAA Patents Committee Penang Malaysia Kay Konishi Co-chair of APAA Patents Committee.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Update on IP High Court -Trend of Determination on Inventive Step in IP High Court in comparison with the JPO- JPAA International Activities Center Toshifumi.
Olek Pawlowski IEOR 190 Spring 2009 UC Berkeley Explaining the basic concepts of the landmark Supreme Court patent case of KSR vs. Teleflex and specifically.
Prosecution Group Luncheon May, Obviousness—In re Kao (FC 2011) BPAI affirms obviousness rejection: using reference formula, POSA can replace reference’s.
Prosecution Group Luncheon Patents August, The Disk is Only As Good As the Software CyberSource Corp. v. Retail Decisions, Inc. (Fed Cir. 2011)
Prosecution Lunch October Bits and Pieces from the Patent Side Crowing about reduction in pending cases –From 750K a year ago to about 708K now.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
PTAB Litigation 2016 Part 6 – Patent Owner Response 1.
Class 24: Finish Remedies, then Subject Matter Patent Law Spring 2007 Professor Petherbridge.
This Webcast Will Begin Shortly If you have any technical problems with the Webcast or the streaming audio, please contact us via at:
Introduction to Intellectual Property Class of Sept
The Challenge of Biotech Patent Eligibility in the United States:
Prosecution Group Luncheon
Unless otherwise noted, the content of this course material is licensed under a Creative Commons Attribution 3.0 License.
Processes Which Employ Non-Obvious Products
Options to Protect an Invention: the Patent Cooperation Treaty (PCT) and Trade Secrets Hanoi October 24, 2017 Peter Willimott Senior Program Officer WIPO.
Patents VI Infringement & the Doctrine of Equivalents
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
ChIPs Global Summit, September 15, 2016
Patents IV Nonobviousness
Lord Neuberger in Actavis v Eli Lilly [2017] RPC 21, para. 57.
Bromberg & Sunstein LLP
How to examine a Supreme Court Case
Prosecution Luncheon Patent March 2017
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Protection of AI Inventions in Japan
Copyright Pearson Prentice Hall
Update and Practical Considerations
Advanced Patent Law Institute Palo Alto
Copyright © 2011 Pearson Education, Inc. All rights reserved.
(Outmoded) “Point of Novelty” Test
Subject Matter Eligibility
Copyright Pearson Prentice Hall
A tutorial and update on patentable subject matter
Examination Issues: Immunology
Jody Blanke and Janine Hiller August 7, 2017
Presentation transcript:

Prosecution Lunch September 2010

Data Visualization Center: Patent “Dashboard” Data Visualization Center: www.uspto.gov/dashboards/patents/main.dashxml Access to pendency and operations data 1st OA pendency – Backlog Annualized production – No. of examiners Allowance rate – “Inventory Position” Information updated monthly 

Dashboard—Rev ‘Em Up!

Examination Guidelines Update—Obviousness 2010 KSR Guidelines Update 75 Fed. Reg. 53643 (www.uspto.gov/patents/law/notices/2010.jsp) Follows up on 2007 KSR Guidelines Reviews FC cases, provides “teaching points”

Examination Guidelines Update—Examples Rationale: Combining Prior Art Elements Claim may be nonobvious if art teaches away from combination and combination yields more than predictable results (Crocs, Inc. v. USITC) Claim likely obvious if known elements would be expected to maintain respective properties, or if POSA would see reason to combine and would know how to do so (Sundance Inc. v. DeMonte Fabricating; Ecolab, Inc. v. FMC Corp.) Predictability encompasses capability of being combined, expectation the combination will work (DePuy Spine v. Medtronic Sofamor Danek)

Examination Guidelines Update Other Guideline Areas Substituting One Element for Another “Obvious to Try” Per PTO: fear that few claims will survive under this rationale “unfounded” in light of recent cases FC Cases on Consideration of Evidence

When is a Preamble a Limitation? American Medical Systems, Inc. v. Biolitec, Inc. (FC Sept. 13, 2010) Method “for photoselective vaporization of tissue” Trial court: construes preamble as limiting “Photoselective vaporization” is a “fundamental characteristic” of invention Claim requires wavelength “highly absorptive in the tissue . . . [and] only to a negligible degree by water” Summary judgment for defendant

When is a Preamble a Limitation? General principle: preamble is not limiting Can limit if it recites essential structure or steps, or necessary to give “life, meaning, and vitality” Not limiting if it is “merely duplicative” of elements in the body, or “merely gives a descriptive name” to the elements in the body Here, preamble is such a descriptive name; it provides nothing extra over elements in body Dissent: rule “that all preambles are limiting would make better sense and would better serve the interests of all concerned”

Prosecution Lunch September 2010